A Clinical Trial to Evaluate the Effects of Broc Shot Capsules on Skin Appearance and Comfort in Adults With Reactive, Blemish-Prone, or Hormonally Affected Skin

November 12, 2026 updated by: BrocShot Inc

This is a randomized, double-blind, placebo-controlled, fully decentralized (remote) clinical trial evaluating the effects of Broc Shot Capsules on skin appearance and comfort in adults with reactive, blemish-prone, or hormonally affected skin. Fifty participants aged 18-65 years will be randomly assigned in a 1:1 ratio to receive either Broc Shot Capsules (active) or matched placebo capsules for 8 weeks.

Participants will take 2 capsules once daily and complete self-reported questionnaires and standardized self-captured skin photographs at Baseline, Week 4, and Week 8 via a secure online study platform. Expert dermatologist grading of photographs will be conducted remotely at each timepoint. The study is designed to substantiate consumer product claims related to visible skin improvement and participant-reported skin comfort, and is not intended to evaluate treatment of any clinical dermatological disease.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Nevada
      • Las Vegas, Nevada, United States, 89101
        • Citruslabs

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults aged 18 to 65 years (inclusive) at the time of consent.
  • Self-reported skin concerns matching at least one of the following descriptions: I have red, itchy skin patches
  • I have dry, flaky/scaley skin patches
  • my skin has blemishes such as pimples, discoloured papules (small, tender bumps that are pink/red/purple/or darker than your natural skin tone) or pustules (a distinct white or yellow pus-filled center surrounded by a red base).
  • Generally healthy adults who are willing and able to follow the study protocol for the full 8-week duration, including taking 2 capsules of the study product once daily for 8 consecutive weeks without skipping days, answering questionnaires at Baseline, Week 4, and Week 8, and following the photograph submission protocol at Baseline, Week 4, and Week 8.
  • Willing to avoid initiating any new topical or oral skincare products, prescription medications targeting skin, or other dietary supplements specifically marketed for skin benefit during the study period.
  • Participants currently using such products who have been using them consistently for at least 3 months prior to enrollment and are willing to continue unchanged throughout the study are eligible.
  • Willing to maintain their current diet, lifestyle, sleep pattern, sun exposure habits, and skincare routine for the duration of the trial.
  • Resides within the United States.
  • Access to a smartphone or computer with internet connection and the ability to use the Citruslabs digital study platform.

Exclusion Criteria:

  • Known allergy, hypersensitivity, or intolerance to broccoli, horseradish, other cruciferous vegetables (Brassicaceae family), or any component of the study product or placebo capsule.
  • Currently pregnant, breastfeeding, or planning to become pregnant during the study period.
  • Currently taking prescription anticoagulant medications (e.g., warfarin, apixaban, rivaroxaban) due to the potential for product ingredients to interact with anticoagulant activity.
  • History of a severe or unstable medical condition that, in the opinion of the study team, would prevent safe participation or adherence to the protocol, including active cancer treatment.
  • Currently using any oral, topical, or biologic prescription medication specifically indicated for a diagnosed dermatological condition, unless the regimen has been stable for at least 3 months and no changes are planned during the study period.
  • Planned dermatological procedures during the study period (e.g., chemical peels, laser treatments, microneedling, injectable cosmetic procedures) that could confound skin appearance assessments.
  • Currently enrolled in another clinical or consumer research study, or plans to enroll in any such study during the 8-week study period.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo Comparator

Participants will take 2 capsules once daily, with their first meal of the day, avoiding administration with hot or acidic liquids.

Experimental: BrocShot Collagen

Participants will take 2 capsules once daily, with their first meal of the day, avoiding administration with hot or acidic liquids.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinician-Assessed Change in Overall Skin Appearance
Time Frame: Baseline to Week 8

Change from Baseline in overall skin appearance graded by a qualified dermatologist reviewing participant-submitted digital photographs using a binary Yes/No improvement scale assessing overall skin health, pigmentation, dryness, brightness, scarring, blemishes, redness, and flaking

Baseline to Week 8

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Participant-Reported Change in Skin Appearance
Time Frame: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin appearance assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Clarity
Time Frame: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin clarity assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Calmness
Time Frame: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin calmness assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Visible Skin Concerns
Time Frame: Baseline, Week 4, and Week 8

Change from Baseline in self-reported visible skin concerns assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Texture
Time Frame: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin texture assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Luminosity
Time Frame: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin luminosity assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Age Appearance
Time Frame: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin age appearance assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Itching and Irritation
Time Frame: Baseline, Week 4, and Week 8

Change from Baseline in self-reported itching and irritation assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Comfort
Time Frame: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin comfort assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Confidence
Time Frame: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin confidence assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

January 1, 2027

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • BROCS-84181

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.